Nanobiotix Shares Bounce Nearly 5%, Among Top Gainers in SBF 120
The French biotech regains momentum at the start of the week, following several pressured sessions. The stock benefits from a broadly positive Parisian market, following easing geopolitical tensions in the Middle East. The rebound occurs as the stock seeks stabilization after a record high in mid-May.
A 4.84% Rebound Brings the Stock Back to the Forefront of the SBF 120
Nanobiotix advances 4.84% to €32.08 in mid-morning trading, while the SBF 120 gains 1.09% during the session. The stock is among the top performers in the broad Parisian index, in a market buoyed by the US-Iran framework agreement on the Strait of Hormuz and the retreat of Brent crude prices. However, the biotech has no direct link to this energy context, which remains merely a backdrop for the session. Today's movement mitigates part of the monthly decline, which still stands at -30.5%. Over three months, performance turns positive again (+11.2%), while the annual gain remains spectacular at over 620%. The stock trades at €32.08, slightly above the MM50 (€31.92) but below the MM20 at €33.34 (a gap of -3.78%), reflecting the digestion phase after the historical peak in mid-May at €47.66. The RSI at 44 remains in the neutral zone, without a marked directional signal.
Consolidation Following a Capital Increase and Anticipated Clinical Data
The rebound comes just days after a series of significant corporate announcements. In early June, the biotech completed a capital increase of €86.1 million through pre-financed warrants, bringing its net cash to €42.1 million as of March 31, 2026. Concurrently, preliminary phase 2 data on JNJ-1900 (NBTXR3) for inoperable lung cancer were presented, with a response observed in 6 of the 7 treated patients. On June 2, the company also joined the Euronext Tech Leaders segment, aiming for greater exposure among international investors. During the first quarter of 2026 report, the company identified the advancement of clinical studies on JNJ-1900 and the strengthening of the Nanoprimer platform as key growth drivers, while noting the limited progress of the current standard of care in inoperable NSCLC as among the risks. The stock remains 44.8% above its MM200 at €22.16, illustrating the extent of the rally still achieved over twelve months. The MM20 at €33.34 remains the next technical marker on the trajectory of the rebound.
